On October 7, 2022, Convey Health Solutions, Inc. (the Borrower) and an indirect wholly owned subsidiary of the Company, entered into Amendment No. 6, by and among, inter alios, the Borrower, as borrower, Ares Capital Corporation, as administrative agent and collateral agent, and the lenders and agents party thereto, to the First Lien Credit Agreement, dated as of September 4, 2019, as amended prior to the date hereof (the Credit Agreement"). Amendment No.

6 amends the Credit Agreement to provide for, among other things, (i) a first lien incremental term loan facility (the Incremental Term Loan Facility") in an aggregate principal amount of $180,000,000 and (ii) replacement of the London interbank offered rate (LIBOR) benchmark provisions with secured overnight financing rate (SOFR) benchmark provisions, subject to a credit spread adjustment of 0.10% per annum. The proceeds of the term loans borrowed under the Incremental Term Loan Facility (the Incremental Term Loans") were used to directly and/or indirectly finance the Merger and pay fees and expenses related thereto. The Incremental Term Loans will mature on September 4, 2026, will bear interest at an annual rate equal to, at the option of the Borrower, (i) the Adjusted Term SOFR (as defined in the Credit Agreement) (subject to a floor of 0.75% per annum) plus 5.25% for Term SOFR Rate Loans (as defined in the Credit Agreement) or (ii) a customary base rate plus 4.25% for Base Rate Loans (as defined in the Credit Agreement), and will amortize in quarterly installments at a rate of 1.00% per annum.

Any repricing transaction with respect to the Incremental Term Loans prior to February 12, 2024 will be subject to a prepayment premium of 1.00%, subject to certain exceptions set forth in the Credit Agreement.